• R Freynhagen, P Busche, C Konrad, and M Balkenohl.
• Klinik für Anästhesiologie, Universitätsklinikum Düsseldorf. Freynhagen@med.uni-duesseldorf.de
• Schmerz. 2006 Aug 1;20(4):285-8, 290-2.

BackgroundThe data from a previously published 12-week randomised, double-blind, placebo-controlled multicentre study on the efficacy and safety of pregabalin were analyzed for time to onset of analgesic action with neuropathic pain.Patients And MethodsA total of 338 patients with postherpetic neuralgia or painful diabetic peripheral neuropathy were treated with flexible or fixed regimens of pregabalin at daily doses of up to 600 mg/day (n=141 and 132, respectively) or placebo (n=65).ResultsUnder fixed dose treatment, a decrease of one full point on the 11-point numerical rating pain scale was reached on day 1, two full points on day 13, and three full points on day 23 (under flexible dose pregabalin: on days 6, 17 and 30). In both treatment arms, pain reduction was statistically significant (P=0.001, P=0.002 vs placebo, respectively).ConclusionIn patients with chronic neuropathic pain, the analgesic effect of both pregabalin treatment regimens was high and associated with a rapid time to onset.

19 keywords...

hide…